Lazard Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.55M Sell
340,255
-1,500,673
-82% -$40M 0.02% 430
2025
Q4
$45.8M Buy
1,840,928
+62,895
+4% +$1.59M 0.08% 213
2025
Q3
$45.3M Buy
1,778,033
+583,659
+49% +$14.4M 0.06% 209
2025
Q2
$29M Buy
1,194,374
+314,931
+36% +$7.34M 0.04% 304
2025
Q1
$22.3M Buy
879,443
+675,243
+331% +$17.7M 0.03% 327
2024
Q4
$5.42M Sell
204,200
-50,586
-20% -$1.37M 0.01% 621
2024
Q3
$7.37M Sell
254,786
-14,091
-5% -$411K 0.01% 537
2024
Q2
$7.52M Sell
268,877
-426,027
-61% -$11.7M 0.01% 574
2024
Q1
$19.3M Sell
694,904
-1,264,445
-65% -$35.1M 0.02% 395
2023
Q4
$56.4M Sell
1,959,349
-100,235
-5% -$3.03M 0.07% 201
2023
Q3
$68.3M Sell
2,059,584
-185,703
-8% -$6.57M 0.09% 174
2023
Q2
$82.4M Buy
2,245,287
+154,787
+7% +$6.02M 0.1% 160
2023
Q1
$85.3M Buy
2,090,500
+209,515
+11% +$9.05M 0.11% 155
2022
Q4
$96.4M Buy
1,880,985
+122,416
+7% +$5.87M 0.13% 137
2022
Q3
$77M Sell
1,758,569
-156,287
-8% -$7.59M 0.11% 165
2022
Q2
$100M Sell
1,914,856
-169,091
-8% -$8.62M 0.14% 136
2022
Q1
$108M Buy
2,083,947
+1,275,423
+158% +$66.2M 0.13% 152
2021
Q4
$47.7M Buy
808,524
+2,522
+0.3% +$125K 0.05% 296
2021
Q3
$34.7M Sell
806,002
-714,884
-47% -$31.7M 0.04% 355
2021
Q2
$59.6M Sell
1,520,886
-1,331,187
-47% -$51.8M 0.07% 244
2021
Q1
$103M Sell
2,852,073
-485,599
-15% -$17.2M 0.13% 142
2020
Q4
$123M Sell
3,337,672
-14,953,399
-82% -$548M 0.16% 124
2020
Q3
$637M Buy
18,291,071
+669,086
+4% +$23.5M 0.9% 22
2020
Q2
$547M Buy
17,621,985
+2,360,511
+15% +$80.2M 0.84% 22
2020
Q1
$473M Buy
15,261,474
+2,762,850
+22% +$94.1M 0.87% 26
2019
Q4
$465M Buy
12,498,624
+4,320,112
+53% +$154M 0.66% 39
2019
Q3
$279M Sell
8,178,512
-1,710,977
-17% -$62.2M 0.46% 56
2019
Q2
$406M Sell
9,889,489
-2,075,482
-17% -$82.4M 0.66% 44
2019
Q1
$482M Sell
11,964,971
-6,060
-0.1% -$243K 0.79% 36
2018
Q4
$496M Sell
11,971,031
-2,841,143
-19% -$118M 0.91% 26
2018
Q3
$619M Sell
14,812,174
-628,574
-4% -$24.2M 1% 24
2018
Q2
$531M Sell
15,440,748
-4,094,793
-21% -$140M 0.92% 27
2018
Q1
$658M Buy
19,535,541
+1,424,447
+8% +$49M 1.12% 24
2017
Q4
$622M Buy
18,111,094
+203,883
+1% +$6.95M 1.07% 25
2017
Q3
$607M Sell
17,907,211
-183,796
-1% -$5.91M 1.1% 24
2017
Q2
$577M Sell
18,091,007
-13,159,959
-42% -$415M 1.08% 26
2017
Q1
$1.01B Sell
31,250,966
-5,023,010
-14% -$158M 1.91% 8
2016
Q4
$1.12B Buy
36,273,976
+8,521,347
+31% +$260M 2.28% 3
2016
Q3
$892M Buy
27,752,629
+4,304,965
+18% +$144M 1.77% 11
2016
Q2
$783M Sell
23,447,664
-5,345,159
-19% -$171M 1.65% 12
2016
Q1
$810M Buy
28,792,823
+4,126,745
+17% +$118M 1.77% 11
2015
Q4
$755M Buy
24,666,078
+125,359
+0.5% +$3.94M 1.73% 11
2015
Q3
$731M Buy
24,540,719
+1,573,574
+7% +$50.5M 1.75% 12
2015
Q2
$731M Buy
22,967,145
+740,609
+3% +$24.1M 1.53% 14
2015
Q1
$734M Buy
22,226,536
+404,111
+2% +$12.8M 1.58% 11
2014
Q4
$645M Sell
21,822,425
-1,085,715
-5% -$31.1M 1.38% 14
2014
Q3
$643M Sell
22,908,140
-6,387,518
-22% -$179M 1.38% 14
2014
Q2
$825M Buy
29,295,658
+2,637,816
+10% +$75.2M 1.72% 7
2014
Q1
$812M Buy
26,657,842
+1,271,313
+5% +$37.9M 1.81% 4
2013
Q4
$738M Sell
25,386,529
-5,443,513
-18% -$158M 1.64% 6
2013
Q3
$840M Sell
30,830,042
-755,592
-2% -$20.6M 1.99% 3
2013
Q2
$839M Buy
+31,585,634
New +$873M 1.99% 5

Other funds holding PFE

Lazard Asset Management's PFE Position: Q1 2026 in Review

Lazard Asset Management reduced its Pfizer (PFE) stake by 82% in Q1 2026, selling an estimated $40M and leaving 340,255 shares worth $9.55M. The position accounts for 0.02% of the portfolio, ranked #430.

Lazard Asset Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.12B in Q4 2016. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Lazard Asset Management held 340,255 shares of Pfizer worth $9.55M as of Q1 2026.
  • Lazard Asset Management sold 1,500,673 Pfizer shares in Q1 2026, an estimated $40M.
  • Pfizer made up 0.02% of Lazard Asset Management's portfolio in Q1 2026, its #430 holding.
  • Lazard Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Lazard Asset Management's Pfizer position peaked at $1.12B in Q4 2016.
  • 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.